The JAK inhibitor ruxolitinib can clearly reduce the expression of SOCS3 in a number of cellular contexts outside of MPN [82, 83] and we and others have shown that RNA sequencing data confirm reduced expression in MPN cell line models [84, 85]. Here, SOCS3 is linked to myeloproliferative neoplasm.